Merck MSD

Activities: Regulatory Infection Control Cardiovascular Mental Health Pharmaceutical Cognitive Sun Care

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. Moderna bags $590m US investment to accelerate mRNA-based bird flu vaccine development The pharmaceutical company's investigational influenza vaccine targets the H5 and H7 varieties, and is currently being prepared for Phase III trials
  3. Servier expands AI partnership with Google Cloud to bolster pharma R&D efforts The company will utilise AI and generative AI technology to optimise its therapeutic target/drug discovery and development processes
  4. Kindeva Drug Delivery to supply nerve agent antidote autoinjector to the US SNS The CDMO will produce the DuoDote autoinjecter containing atropine and pralidoxime chloride at its fill/finish manufacturing facility in St Louis, Missouri
  5. Navin Molecular constructs a new R&D facility in Dewas, India The laboratory will enhance the CDMO's small molecule laboratory- and kilo-scale process development capabilities, as well as its analytical development and testing capacity

Upcoming event

Pharma Packaging and Labelling Forum

5–6 March 2025 | Conference | San Diego, US See all

Related Content

Manufacturing

Merck buys WuXi Biologics' Irish vaccine manufacturing facility for $500m

This sale is part of WuXi Biologics' initiative to build business in the face of the BIOSECURE act, as the company places a stronger focus on building its CDMO services in China
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Regulatory

Merck's sacituzumab tirumotecan granted Breakthrough Therapy Designation by the FDA

The antibody-drug conjugate (ADC) can be used to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Manufacturing

Merck appoints Surendralal L. Karsanbhai to its board of directors

The President and CEO of Emerson Electric will work with the 13-strong board to oversee the management of Merck's global business endeavours
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Manufacturing

Merck bolsters its ADC CDMO offering with €71m Missouri manufacturing site expansion

The facility's expansion has tripled its ADC manufacturing capacity, bolstering Merck's CDMO offering for current and new clients
Subscribe now